IMUXImmunic Inc

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026...

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials...

(RTTNews) - Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1...

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer PR Newswire NEW YORK, May 27, 2026 Proven Leader with Deep Multiple Sclerosis Expertise; Played Key...

Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic's Phase 3 trials in 2026.read more...

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout...

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the...

Lifesci Capital raised shares of Immunic to a "strong-buy" rating in a report on Monday...

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Immunic in a report issued on Thursday, April 30th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.20) per share for t...